HATs off to epigenetics

How AbbVie is expanding its reach in cancer epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an inhibitor of two histone acetyltransferases, a class of epigenetic enzymes largely untouched by drug developers.

In a paper published in Nature last month,

Read the full 581 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE